Built for biotech investors

You had the right thesis. Did it still hold?

For each company we cover: what the investment case depends on, whether each part is still holding, and the next decision that could change it.

Tracking 200+ biotech companies · 21 FDA decisions ahead

Track your first thesis

Free 7-day trial · no card needed

SMMTSummit TherapeuticsChallengedMedium conviction

FDA's November 14 decision is next; Datroway collaboration adds breast cancer development

Thesis checklist

  • FDA approves ivonescimab after EGFR-targeted therapyAwaiting evidence

    Next: FDA's decision and the population covered by any approved label.

  • HARMONi-3 extends benefit to first-line lung cancerAwaiting evidence

    Next: HARMONi-3 progression-free survival results, with each histology assessed separately.

  • Survival benefit over Keytruda holds upSupported

    Next: Global comparative results, distinguishing HARMONi-3 chemotherapy combinations from HARMONi-2 monotherapy.

  • Funding covers launch and the Phase 3 programSupported

    Next: Updated cash, spending, and conditional runway guidance incorporating launch preparation and expanded trial commitments.

Next decision point

FDA decision on ivonescimab after EGFR-targeted therapy

November 14, 2026 PDUFA goal action date

Does FDA approve ivonescimab plus chemotherapy for EGFR-mutant lung cancer after a third-generation EGFR inhibitor?

Live from the Summit Therapeutics page

The biggest losses rarely come from a bad thesis.

They come from failing to recognize when the thesis changed. Biotech doesn't drift, it lurches: a CRL, a trial readout, an FDA panel vote. You're left holding a position you haven't re-evaluated in months.

The Terminal catches the change, across everything you follow.

  • Oct 21, 2026Keros Therapeutics (KROS)ChallengedIntact

    Keros dosed the first patient in rinvatercept's Phase 2 in Duchenne muscular dystrophy, with initial data due in 1H 2027; Takeda's elritercept Phase 3s are paying milestones

  • Oct 16, 2026Palatin Technologies (PTN)IntactChallenged

    Palatin reports going-concern doubt with $7.5 million in cash as it prepares its first MC4R obesity trials for 2027

  • Oct 16, 2026Recursion Pharmaceuticals (RXRX)ChallengedIntact

    Recursion raised $200 million and extended its runway into 2029 as REC-4881's polyp data held up; FDA talks will set the 2H 2027 registrational start

  • Oct 16, 2026NervGen Pharma (NGEN)IntactChallenged

    NVG-291 enters Phase 3 under partial FDA clinical hold; 2028 trial outcome hinges on hold removal and new capital

  • Oct 15, 2026Corbus Pharmaceuticals (CRBP)ChallengedIntact

    Nectin-4 ADC with 43% ORR in OPSCC enters registrational trial; interim readout will determine accelerated approval path

Proof, not a pitch

A Thesis history, dated when it happened.

Replimune Group's history as it appears on its page. Each entry is dated to the event that caused it, and a verdict is never changed after the fact.

  1. Oct 1, 2026 · Challenged · current

    TUDRIQEV launched under accelerated approval; RP2's REVEAL transition in Q1 2027 is next

  2. Aug 6, 2026 · Challenged

    TUDRIQEV approved; IGNYTE-3 confirmation and long-term funding are the next tests

  3. Jul 30, 2026 · Challenged

    Two CRLs overcome by a 10-3 adcom vote, but a third FDA rejection would exhaust both cash and the approval path before RP2 matures

  4. Jun 26, 2026 · Challenged

    Two CRLs on single-arm IGNYTE data; a third FDA decision on the same dataset arrives before the cash runs out

  5. May 29, 2026 · Challenged

    RP1's third FDA submission tests whether a prioritized resubmission can overcome two CRLs in anti-PD-1-failed melanoma before runway expires

  6. Apr 10, 2026 · Broken

    FDA Complete Response Letter for RP1 + nivolumab BLA

See the full history

Why not just use AI?

AI answers questions.
readouts.io tracks whether your thesis still holds.

AI

Knows facts and summarizes filings
Answers questions about a single document
Any read on the past already knows the outcome
Can't tell you if the story changed

readouts.io

Wrote down what it thought before it knew the outcome
Dated, and tied to the filing that caused it
Tracks the evolution of each Thesis over time
Tells you whether your original reason for owning the stock still exists

Built for investors who own too many positions to track manually.

The problem isn't “I don't know how to read an 8-K.” The problem is “I own 20 biotech stocks, each one binary enough to double or halve on a single FDA letter, and I don't have time to continuously reassess each thesis.” readouts.io pays for itself the first time it catches a thesis change you would have missed.

Early adopter
$20/ month$30

7-day free trial, no card needed — then $20/month forever, locked in as an early adopter

Every covered company, one Thesis — updated as the story changes. Follow what you own, ask what you need to know.

With a subscription

Why each checklist item is in its state
Strong, inconclusive and weak outcomes for each next decision
The reasoning behind every entry in the Thesis history
Competitive landscape
Email alerts when a Thesis you follow changes
Ask any question about any company

Free for everyone

The Thesis and its status (Intact, Challenged or Broken) for every covered company
The Thesis checklist and next decision point, where available
Every catalyst date, linked to its source
The dated history of each Thesis
Pipeline, drug pages and the catalyst calendar
Track your first thesis

Free to sign up — your 7-day trial starts immediately, no card needed. Nothing is charged unless you choose to subscribe.